Keryx Biopharmaceuticals Inc (KERX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

750 LEXINGTON AVENUE NEW YORK, NY 10022

Acquires, develops and commercializes novel pharmaceutical products for the treatment of life-threatening diseases. As of Dec. 31, 2005, the company's lead product candidates were Sulonex for the treatment of diabetic nephropathy and KRX-0401 for the treatment of multiple forms of cancer.

View SEC Filings from KERX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) 0 (0.0%)
13F shares: 1 1 0.0% 0
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls 0
Total Puts 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KERX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KERX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CAMERON KEVIN J

  • Director
No longer subject to file 2018-12-12 0

REGAN DANIEL PAUL

  • Director
No longer subject to file 2018-12-12 0

NEYLAN JOHN F. CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-12-12 0

HOLMES SCOTT A CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2018-12-12 0

ROGERS MICHAEL W

  • Director
No longer subject to file 2018-12-12 0

GILMAN STEVEN C

  • Director
No longer subject to file 2018-12-12 0

MORRISON JODIE POPE INTERIM CEO

  • Officer
  • Director
No longer subject to file 2018-12-12 0

HEFFERNAN MICHAEL THOMAS

  • Director
No longer subject to file 2018-12-12 0

ENYEDY MARK J

  • Director
No longer subject to file 2018-12-12 0

CARBERRY CHRISTINE A. CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2018-12-11 0

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • Director
  • 10% Owner
No longer subject to file 2018-12-11 0

MADISON GREG PRESIDENT AND CEO

  • Officer
  • Director
566,586 2018-03-20 0

ADAMS BRIAN GENERAL COUNSEL AND SECRETARY

  • Officer
126,069 2018-02-15 0

BUTLER JOHN P.

  • Director
20,000 2017-06-09 0

BAUPOST GROUP LLC/MA

SAK CORP

KLARMAN SETH A

  • 10% Owner
42,016,276 2015-10-14 0

OLIVIERO JAMES F III CHIEF FINANCIAL OFFICER

  • Officer
209,406 2015-07-06 0

FECZKO JOSEPH M

  • Director
120,000 2015-06-17 0

FOWLER WYCHE JR

  • Director
No longer subject to file 2015-06-17 0

KAYE JACK

  • Director
85,000 2015-06-17 0

TARNOK MICHAEL P.

  • Director
338,600 2015-06-17 0

BENTSUR RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
777,209 2015-04-06 0

WEISS MICHAEL S

  • 10% Owner
No longer subject to file 2010-04-23 0

ROSE ERIC A MD

  • Director
155,000 2008-11-14 0

HOENLEIN MALCOLM

  • Director
110,000 2008-11-14 0

HENDERSON CRAIG PRESIDENT

  • Officer
  • Director
0 2007-12-30 0

LEVINE BETH F SVP, GC, CCO AND SECRETARY

  • Officer
0 2007-12-30 0

STIER MARK CHIEF ACCOUNTING OFFICER

  • Officer
0 2007-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments